SPOTLIGHT: Enrollment wrapped on Provenge Phase III

Dendreon is pushing ahead with a new late-stage study of Provenge, completing enrollment in a new Phase III trial the FDA has demanded before it can grant full approval for the cancer therapy. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.